Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01843387 |
Recruitment Status :
Completed
First Posted : April 30, 2013
Last Update Posted : October 14, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diabetic Nephropathy Type 2 Diabetes | Biological: Mesenchymal Precursor Cells (MPCs) | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Controlled, Dose-Escalation Pilot Study to Assess the Safety and Efficacy of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Diabetic Nephropathy and Type 2 Diabetes |
Study Start Date : | July 2013 |
Actual Primary Completion Date : | September 2014 |
Actual Study Completion Date : | September 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1
Mesenchymal Precursor Cells (MPCs) - Dose 1 or Placebo
|
Biological: Mesenchymal Precursor Cells (MPCs)
Single Intravenous Infusion of MPCs Dose 1 or Placebo |
Experimental: Cohort 2
Mesenchymal Precursor Cells (MPCs) - Dose 2 or Placebo
|
Biological: Mesenchymal Precursor Cells (MPCs)
Single Intravenous Infusion of MPCs Dose 2 or Placebo |
- The primary objective of the study is to assess the safety and tolerability of MPC therapy [ Time Frame: 60 Weeks ]
Outcomes include the following safety parameters:
- Number of and percent of subject with adverse events and serious adverse events
- Clinically significant values and shifts from baseline in vital signs, physical examinations and electrocardiograms
- Clinical laboratory tests (hematology, chemistry and urinalysis, flow cytometry with Class I and Class II PRA % with specificity)
- Exploratory assessment of the efficacy of MPC therapy [ Time Frame: 12 Weeks ]
Outcomes include changes from baseline at 12 weeks in the following parameters:
- Renal function (glomerular filtration rate, renal blood flow)
- Serum creatinine
- Urinary albumin and protein excretion
- Glycemic control
- Biomarkers

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years to 85 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Men and women who are ≥ 50 and ≤ 85 years old
- Subjects diagnosed with type 2 diabetes at least 2 years prior to Screening
- Subjects with diabetic nephropathy and CKD stage 3b-4
- Albumin-to-creatinine ratio (ACR) from a spot urine sample >30 and < 3000 mg/g at Screening
- Subjects must be receiving standard of care treatment for their diabetic nephropathy with an angiotensin converting enzyme inhibitor (ACEi) and/or an angiotensin II receptor blocker (ARB) for at least 12 weeks prior to Screening.
- HbA1c < 10.0% at Screening
Exclusion Criteria:
- Prior participation in any stem cell study
- Women of childbearing potential
- Potentially unreliable subjects and those judged by the Investigator to be unsuitable for the study
- History of active substance abuse (including alcohol) within the past 2 years. Current alcohol abuse is defined as daily consumption of >3 alcoholic beverages (i.e. > 21 alcoholic beverages per week)
- Body weight >150 kg
- Subjects with non-diabetic renal disease e.g. known polycystic kidney disease
- Subjects with a history of a renal transplant or who have had prior dialysis within 3 months of Screening and/or have not maintained a stable level of kidney function within 3 months of Screening
- Current or history within 6 months of Screening of NYHA Class III or IV heart failure
- Myocardial infarction or stroke within 6 months prior to Screening
- Any concurrent medical condition/disorder or clinically symptomatic cardiovascular, gastrointestinal, hematological, pulmonary, acute or chronic infectious disease, active retinal disease or other disorder which in the Investigator's opinion would interfere with the subjects ability to complete the trial, would require administration of treatment that could affect the interpretation of the efficacy and safety variables or would preclude safe involvement in the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01843387
Australia | |
Monash Universtiy | |
Clayton, Australia | |
Melbourne Renal Research Group | |
Melbourne, Australia |
Study Director: | K Segal, PhD | Mesoblast, Ltd. |
Responsible Party: | Mesoblast, Ltd. |
ClinicalTrials.gov Identifier: | NCT01843387 |
Other Study ID Numbers: |
MSB-DN001 |
First Posted: | April 30, 2013 Key Record Dates |
Last Update Posted: | October 14, 2016 |
Last Verified: | October 2016 |
Diabetic nephropathy Chronic kidney disease Metabolic disease Diabetes mellitus, type 2 |
Kidney Diseases Diabetic Nephropathies Diabetes Mellitus, Type 2 Diabetes Mellitus Glucose Metabolism Disorders |
Metabolic Diseases Endocrine System Diseases Urologic Diseases Diabetes Complications |